LAGOON

The LAGOON study, OP-115, is a non-interventional study (NIS), of melphalan flufenamide (melflufen, Pepaxti®) in combination with dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM) according to the approved label.

This NIS aims to observe the effects of the use of melflufen, in combination with dexamethasone, in clinical practice in Spain. The patients in this type of study will receive the same treatment and diagnostic procedures as they would have received if they were not included in this study.

The study started in Q1 2025 and is planning to enroll up to 50 patients in Spain in real-life clinical practice.